128 related articles for article (PubMed ID: 29161363)
21. A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.
Fizazi K; Delva R; Caty A; Chevreau C; Kerbrat P; Rolland F; Priou F; Geoffrois L; Rixe O; Beuzeboc P; Malhaire JP; Culine S; Aubelle MS; Laplanche A
Eur Urol; 2014 Feb; 65(2):381-6. PubMed ID: 24094847
[TBL] [Abstract][Full Text] [Related]
22. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.
Sonneveld DJ; Hoekstra HJ; van der Graaf WT; Sluiter WJ; Mulder NH; Willemse PH; Koops HS; Sleijfer DT
Cancer; 2001 Apr; 91(7):1304-15. PubMed ID: 11283931
[TBL] [Abstract][Full Text] [Related]
23. Bleomycin, etoposide and cisplatinum (BEP) chemotherapy for metastatic germ cell tumours: treatment outcomes at UKM medical centre, Malaysia.
Azrif M; Leong YK; Aslan NM; Fong KV; Ismail F
Asian Pac J Cancer Prev; 2012; 13(6):2467-71. PubMed ID: 22938405
[TBL] [Abstract][Full Text] [Related]
24. Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes.
Necchi A; Nicolai N; Mariani L; Raggi D; Farè E; Giannatempo P; Catanzaro M; Biasoni D; Torelli T; Stagni S; Milani A; Piva L; Pizzocaro G; Gianni AM; Salvioni R
Ann Oncol; 2013 Nov; 24(11):2887-92. PubMed ID: 23860612
[TBL] [Abstract][Full Text] [Related]
25. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
[TBL] [Abstract][Full Text] [Related]
26. Low Survival in Poor Prognosis Metastatic Germ Cell Cancer in Belarus.
Rolevich AI; Borodin DM; Rabcheuski AN; Ivanitskaya TA; Semenov SA; Artsiushkevich LV; Sukalinskaya AV; Zhavrid EA; Krasny SA; Konoplya NE; Polyakov SL
JCO Glob Oncol; 2021 Jan; 7():63-71. PubMed ID: 33434070
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014.
Adra N; Althouse SK; Liu H; Brames MJ; Hanna NH; Einhorn LH; Albany C
Ann Oncol; 2016 May; 27(5):875-9. PubMed ID: 26861605
[TBL] [Abstract][Full Text] [Related]
28. Long-Term Survival of Good-Risk Germ Cell Tumor Patients After Postchemotherapy Retroperitoneal Lymph Node Dissection: A Comparison of BEP × 3 vs. EP × 4 and Treating Institution.
Cary C; Jacob JM; Albany C; Masterson TA; Hanna NH; Einhorn LH; Foster RS
Clin Genitourin Cancer; 2018 Apr; 16(2):e307-e313. PubMed ID: 29104087
[TBL] [Abstract][Full Text] [Related]
29. Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation.
Raggi D; Mariani L; Giannatempo P; Lo Vullo S; Giardiello D; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Calareso G; Magni M; Di Nicola M; Verzoni E; Grassi P; Procopio G; De Braud F; Pizzocaro G; Salvioni R; Necchi A
Urol Oncol; 2015 Jul; 33(7):332.e19-24. PubMed ID: 25985712
[TBL] [Abstract][Full Text] [Related]
30. Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumors.
Pectasides D; Pectasides E; Papaxoinis G; Xiros N; Kamposioras K; Tountas N; Economopoulos T
Urol Oncol; 2010; 28(6):617-23. PubMed ID: 19110454
[TBL] [Abstract][Full Text] [Related]
31. Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
Liu YL; Manning-Geist BL; Knezevic A; Deng L; Bromberg M; Funt SA; Meisel JL; Zivanovic O; Roche KL; Sonoda Y; Gardner GJ; Grisham RN; O'Cearbhaill RE; Tew WP; Abu-Rustum NR; Chi DS; Aghajanian C; Feldman DR
Gynecol Oncol; 2023 Mar; 170():93-101. PubMed ID: 36669327
[TBL] [Abstract][Full Text] [Related]
32. The importance of the dose of etoposide in the initial treatment of metastatic germ cell tumors and advances in management of patients that relapse.
Marwaha S; Venner PM; North SA
Can J Urol; 2007 Oct; 14(5):3692-6. PubMed ID: 17949524
[TBL] [Abstract][Full Text] [Related]
33. Oncological outcomes of metastatic testicular cancers under centralized management through regional medical network.
Inai H; Kawai K; Kojima T; Joraku A; Shimazui T; Yamauchi A; Miyagawa T; Endo T; Fukuhara Y; Miyazaki J; Uchida K; Nishiyama H
Jpn J Clin Oncol; 2013 Dec; 43(12):1249-54. PubMed ID: 24101656
[TBL] [Abstract][Full Text] [Related]
34. Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status.
Tryakin A; Fedyanin M; Bulanov A; Kashia S; Kurmukov I; Matveev V; Fainstein I; Gordeeva O; Zakharova T; Tjulandin S
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1817-1823. PubMed ID: 29974210
[TBL] [Abstract][Full Text] [Related]
35. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP).
Culine S; Kerbrat P; Kramar A; Théodore C; Chevreau C; Geoffrois L; Bui NB; Pény J; Caty A; Delva R; Biron P; Fizazi K; Bouzy J; Droz JP;
Ann Oncol; 2007 May; 18(5):917-24. PubMed ID: 17351252
[TBL] [Abstract][Full Text] [Related]
36. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
37. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial.
Fizazi K; Do KA; Wang X; Finn L; Logothetis CJ; Amato RJ
Ann Oncol; 2002 Jan; 13(1):125-34. PubMed ID: 11863094
[TBL] [Abstract][Full Text] [Related]
38. Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3).
Tran B; Ruiz-Morales JM; Gonzalez-Billalabeitia E; Patrikidou A; Amir E; Seidel C; Bokemeyer C; Fankhauser C; Hermanns T; Rumyantsev A; Tryakin A; Brito M; Fléchon A; Kwan EM; Cheng T; Castellano D; Garcia Del Muro X; Hamid AA; Ottaviano M; Palmieri G; Kitson R; Reid A; Heng DYC; Bedard PL
Cancer Med; 2020 Jan; 9(1):116-124. PubMed ID: 31715650
[TBL] [Abstract][Full Text] [Related]
39. Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium.
Bührer E; D'Haese D; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Collette L; Gillessen S; Beyer J
Eur J Cancer; 2024 May; 202():114042. PubMed ID: 38564927
[TBL] [Abstract][Full Text] [Related]
40. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors.
Kondagunta GV; Bacik J; Bajorin D; Dobrzynski D; Sheinfeld J; Motzer RJ; Bosl GJ
J Clin Oncol; 2005 Dec; 23(36):9290-4. PubMed ID: 16361627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
